Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways

Abstract

Background Serotonin reuptake inhibitors (SSRIs) may impair platelet function. Thrombin is a strong platelet agonist causing irreversible aggregation, release of granules' contents, cytoskeletal rearrangement and activation of signalling pathways. We investigated the effects of the SSRI escitalopram (SCIT) on thrombin-induced platelet response.

Methods Isolated platelets were exposed to SCIT and activated with thrombin. We evaluated (1) platelet response by aggregometry and flow cytometry; (2) modifications in cytoskeleton proteins and signalling pathways by electrophoresis and Western blot; and (3) ultrastructural changes in platelets by electron microscopy.

Results SCIT inhibited platelet response to thrombin, measured as platelet aggregation and expression of activation markers CD62-P and CD63 from platelet granules. Platelet aggregation decreased in a dose-dependent manner, reaching statistical significance with SCIT ≥32 µg/mL (65.4 ± 6.8% vs. 77.7 ± 2.5% for controls; p < 0.05). Expression of activation markers was statistically reduced with SCIT ≥20 µg/mL (p < 0.05). SCIT impaired the polymerization of the actin cytoskeleton and association of contractile proteins during activation with thrombin (p < 0.05 with SCIT ≥50 µg/mL). Resting platelets incubated with SCIT became most spherical, with increased platelet roundness (p < 0.01, SCIT 50 µg/mL vs. control). SCIT interfered with signalling pathways modulated by thrombin (RhoA, PKC, Erk1/2 and PI3K/AKT).

Conclusions Our data indicate that SCIT inhibits thrombin-induced platelet response and interferes with cytoskeletal assembly and related signalling pathways, thus resulting in compromised release of granules' contents, reduced platelet activation and aggregation. These mechanisms may explain the antithrombotic benefits observed in patients treated with this SSRI, and could become new therapeutic targets for future antithrombotic strategies.

Keywords

selective serotonin reuptake inhibitor - thrombin - release of granules - cytoskeleton - platelet function

^* Irene Lopez-Vilchez and Didac Jerez-Dolz equally contributed to this work.

• References

• 1 Escolar G, Díaz-Ricart M, Gomez-Gil E. , et al. Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk. Drugs Today (Barc) 2005; 41 (11) 721-743
• 2 Seligman F, Nemeroff CB. The interface of depression and cardiovascular disease: therapeutic implications. Ann N Y Acad Sci 2015; 1345: 25-35
• 3 Lichtman JH, Bigger Jr JT, Blumenthal JA. , et al; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118 (17) 1768-1775
• 4 Kauskot A, Hoylaerts MF. Platelet receptors. Handb Exp Pharmacol 2012; (210) 23-57
• 5 Bongioanni P, Dadone F, Donato M. Human blood platelet as research tool in neuropsychopharmacology. J Neural Transm Suppl 1991; 33: 65-71
• 6 Ehrlich D, Humpel C. Platelets in psychiatric disorders. World J psychiatry 2012; 2 (06) 91-94
• 7 Glassman AH, O'Connor CM, Califf RM. , et al; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288 (06) 701-709
• 8 Carney RM, Freedland KE, Jaffe AS. , et al. Depression as a risk factor for post-MI mortality. J Am Coll Cardiol 2004; 44 (02) 472-474 , author reply 473–474
• 9 Taylor CB, Youngblood ME, Catellier D. , et al; ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62 (07) 792-798
• 10 Lespérance F, Frasure-Smith N, Koszycki D. , et al; CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297 (04) 367-379
• 11 Zafar MU, Paz-Yepes M, Shimbo D. , et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. Eur Heart J 2010; 31 (13) 1573-1582
• 12 Lopez-Vilchez I, Serra-Millas M, Navarro V. , et al. Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment. J Affect Disord 2014; 159: 39-45
• 13 Galan AM, Lopez-Vilchez I, Diaz-Ricart M. , et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102 (03) 511-519
• 14 Lopez-Vilchez I, Diaz-Ricart M, White JG, Escolar G, Galan AM. Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake. Cardiovasc Res 2009; 84 (02) 309-316
• 15 Talib LL, Joaquim HP, Forlenza OV. Platelet biomarkers in Alzheimer's disease. World J Psychiatry 2012; 2 (06) 95-101
• 16 Asor E, Ben-Shachar D. Platelets: a possible glance into brain biological processes in schizophrenia. World J Psychiatry 2012; 2 (06) 124-133
• 17 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407 (6801): 258-264
• 18 Fusté B, Díaz-Ricart M, Jensen MK, Ordinas A, Escolar G, White JG. TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural features. Am J Pathol 2002; 160 (06) 2245-2252
• 19 Diaz-Ricart M, Fuste B, Estebanell E. , et al. Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein Ib. Platelets 2005; 16 (08) 453-461
• 20 Pujadas-Mestres L, Escolar G, Arellano-Rodrigo E, Galán AM. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Drugs Today (Barc) 2013; 49 (07) 425-436
• 21 Depta JP, Bhatt DL. New approaches to inhibiting platelets and coagulation. Annu Rev Pharmacol Toxicol 2015; 55: 373-397
• 22 Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006; 4 (03) 638-647
• 23 Estebanell E, Diaz-Ricart M, Escolar G, Lozano M, Mazzara R, Ordinas A. Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Transfusion 2000; 40 (05) 535-542
• 24 Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43 (05) 453-462
• 25 Carneiro AM, Cook EH, Murphy DL, Blakely RD. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008; 118 (04) 1544-1552
• 26 Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91 (01) 119-128
• 27 Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res 2010; 126 (06) 517-523
• 28 Tseng YL, Chiang ML, Lane HY, Su KP, Lai YC. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. Thromb Res 2013; 131 (04) 325-332
• 29 Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules … or not?. J Thromb Haemost 2015; 13 (12) 2141-2151
• 30 Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68 (04) 435-442
• 31 Blardi P, de Lalla A, Urso R. , et al. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J Clin Psychopharmacol 2005; 25 (03) 262-266
• 32 Piubelli C, Vighini M, Mathé AA, Domenici E, Carboni L. Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge. Int J Neuropsychopharmacol 2011; 14 (06) 834-855
• 33 Kagaya A, Kugaya A, Hayashi T. , et al. Effect of citalopram on the desensitization of serotonin-2A receptor-mediated calcium mobilization in rat glioma cells. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20 (01) 157-166
• 34 Yamaji T, Kagaya A, Uchitomi Y, Yokota N, Yamawaki S. Chronic treatment with antidepressants, verapamil, or lithium inhibits the serotonin-induced intracellular calcium response in individual C6 rat glioma cells. Life Sci 1997; 60 (11) 817-823
• 35 Oruch R, Hodneland E, Pryme IF, Holmsen H. Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane?. Biochim Biophys Acta 2008; 1778 (10) 2165-2176
• 36 Oruch R, Hodneland E, Pryme IF, Holmsen H. In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner. J Chem Biol 2009; 2 (02) 89-103
• 37 White JG, Krumwiede MD, Escolar G. EDTA induced changes in platelet structure and function: influence on particle uptake. Platelets 1999; 10 (05) 327-337
• 38 Zucker MB, Grant RA. Nonreversible loss of platelet aggregability induced by calcium deprivation. Blood 1978; 52 (03) 505-513
• 39 Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99 (12) 1293-1304
• 40 Pleines I, Hagedorn I, Gupta S. , et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 2012; 119 (04) 1054-1063
• 41 Guinebault C, Payrastre B, Racaud-Sultan C. , et al. Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Biol 1995; 129 (03) 831-842
• 42 Nadal-Wollbold F, Pawlowski M, Lévy-Toledano S, Berrou E, Rosa JP, Bryckaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 2002; 531 (03) 475-482
• 43 Scalco AZ, Rondon MU, Trombetta IC. , et al. Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline. J Hypertens 2009; 27 (12) 2429-2436
• 44 Barton DA, Dawood T, Lambert EA. , et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. J Hypertens 2007; 25 (10) 2117-2124
• 45 de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28 (05) 345-367
• 46 Andrade C. Drug interactions in the treatment of depression in patients with ischemic heart disease. J Clin Psychiatry 2012; 73 (12) e1475-e1477
• 47 Thornton JD, Agarwal P, Sambamoorthi U. Use of selective-serotonin reuptake inhibitors and platelet aggregation inhibitors among individuals with co-occurring atherosclerotic cardiovascular disease and depression or anxiety. SAGE Open Med 2016; 4: 2050312116682255